Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 11/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14744646 | 1.00 | ADAMTS5 (0.55) | ADAMTS5MMP12TP53MAPTALDH1A1 | |
| SCHEMBL14744656 | 0.91 | ADAMTS5 (0.64) | ADAMTS5MMP12TP53MAPTALDH1A1 | |
| SCHEMBL29429414 | 0.91 | ADAMTS5 (0.64) | ADAMTS5MMP12TP53MAPTALDH1A1 | |
| SCHEMBL14744626 | 0.88 | ADAMTS5 (0.65) | ADAMTS5MMP12TP53MAPTSMN1; SMN2 | |
| SCHEMBL14744602 | 0.87 | ADAMTS5 (0.61) | ADAMTS5MMP12TP53MAPTALDH1A1 | |
| SCHEMBL14756565 | 0.84 | ADAMTS5 (0.69) | ADAMTS5MMP12MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6278160 | 0.83 | ADAMTS5 (0.64) | ADAMTS5MMP12TP53MAPTALDH1A1 | |
| SCHEMBL15928244 | 0.82 | ADAMTS5 (0.76) | ADAMTS5MMP12TP53MAPTALDH1A1 | |
| SCHEMBL14744685 | 0.82 | ADAMTS5 (0.53) | ADAMTS5MMP12TP53MAPTALDH1A1 | |
| SCHEMBL14756569 | 0.80 | ADAMTS5 (0.71) | ADAMTS5MMP12TP53MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049945-A1 | METHOD OF TREATMENT FOR SOLID TUMORS CONTAINING HYPOXIA AND/OR STROMA FEATURES | WAYNE STATE UNIVERSITY (US) | 2025-02-13 | — | — | US | claimed |
| US-20250049945-A1 | METHOD OF TREATMENT FOR SOLID TUMORS CONTAINING HYPOXIA AND/OR STROMA FEATURES | WAYNE STATE UNIVERSITY (US) | 2025-02-13 | — | — | US | disclosed |
| US-12083187-B2 | Method of treatment for solid tumors containing hypoxia and/or stroma features | WAYNE STATE UNIVERSITY (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240293377-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | US GOV VETERANS AFFAIRS (US) | 2024-09-05 | — | — | US | disclosed |
| US-20230293499-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | US GOV VETERANS AFFAIRS (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293377-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | NFKBIA, NCBP1, NFKB1 | ADAMTS5 3571/4885MMP12 3942/4885TP53 1158/4885 |
| US-20230293499-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMO | NFKBIA, NCBP1, NFKB1 | ADAMTS5 3571/4885MMP12 3942/4885TP53 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.